Navigation Links
Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors
Date:9/16/2009

NEW HAVEN, Conn., Sept. 16 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel drugs for the treatment of multi-antibiotic resistant infections, today announced that Tony Zook has been appointed to the Company's Board of Directors, succeeding Joseph Amprey, MD, Ph.D.

Mr. Zook is President of MedImmune, Chief Executive Officer of AstraZeneca North America, and Executive Vice President of Global Marketing AstraZeneca. MedImmune was acquired by AstraZeneca in June 2007. As Chief Executive Officer of AstraZeneca North America, Mr. Zook oversees AstraZeneca's business in the region, including MedImmune, the AstraZeneca US Business and the AstraZeneca Canadian Business.

A seasoned executive with more than twenty five years of experience in the pharmaceutical industry, Mr. Zook has been CEO of AstraZeneca US since 2006. He has held various sales and marketing positions in the organization, most recently serving as senior vice president for commercial operations. In that role, Zook was responsible for the company's marketing and sales organizations throughout the US. Mr. Zook joined AstraZeneca USA in 1997 and began his career in 1983 at Berlex Laboratories, where he held both sales and marketing positions.

Mr. Zook earned an associate's degree in chemical engineering from Pennsylvania State University and a bachelor's degree in biology from Frostburg University. He is a member of the board for First State Innovation, the Pennsylvania Division of the American Cancer Society and a member of the Board of Trustees for the Healthcare Leadership Council.

"As the most recent appointment to the Rib-X board, we are looking forward to working with Tony during this exciting time in the company's growth," said Dr. Susan Froshauer, President and Chief Executive Officer, Rib-X. "Tony brings years of sales and marketing experience to his new role and we believe his insight will be extremely helpful as our compounds continue to move toward commercialization."

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics, including radezolid, that can be used for the treatment of either community- or hospital-acquired infections. Rib-X has successfully completed Phase 2 trials with delafloxacin (RX-3341), a broad-spectrum fluoroquinolone with potent activity against quinolone-resistant Gram-positive bacteria, including MRSA. Radezolid (RX-1741), an oxazolidinone that was discovered at Rib-X as an oral/IV agent for treatment of serious Gram-positive infections, has completed two Phase 2 trials. The Rx-04 discovery program is developing novel classes of antibiotics active against multi-drug resistant Gram-negative bacteria, and the Rx-02 discovery program is focused on developing an IV/oral macrolide active against methicillin-resistant S. aureus, multidrug-resistant Streptococcus pneumoniae and S. pyogenes. Both delafloxacin and radezolid are currently in late-stage clinical trials.

    For further information please contact:

    Media:
    Irma Gomez-Dib
    FD Life Sciences
    Tel: 212-850-5761
    irma.gomez-dib@fd.com

    Investors:
    John Capodanno
    FD Life Sciences
    Tel: 212-850-5705
    John.capodanno@fd.com


'/>"/>
SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Rib-X Pharmaceuticals to Present at the 49th ICAAC
2. Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram-negative Bacteria
3. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
4. Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
5. Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
6. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
7. Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting
8. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
9. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
10. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
11. Trubion Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
(Date:10/11/2017)... TX (PRWEB) , ... October 11, 2017 , ... ... August compared the implantation and pregnancy rates in frozen and fresh in ... contribution of progesterone and maternal age to IVF success. , After comparing the ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
(Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...
Breaking Biology News(10 mins):